Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia - Wikidata - awgldk - TriplyDB

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

http://www.wikidata.org/entity/Q36651344

about

CAR T Cell Therapy: A Game Changer in Cancer Treatment Genome-Edited T Cell Therapies.Biology and clinical application of CAR T cells for B cell malignancies Chimeric antigen receptor-modified T cells strike back.Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia.Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.Retroviral Vectors for Cancer Gene Therapy.Development of CAR T cells designed to improve antitumor efficacy and safety.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.Detection of Replication Competent Lentivirus Using a qPCR Assay for VSV-G.Incorporation of functional elements enhances the antitumor capacity of CAR T cells.Ibrutinib treatment improves T cell number and function in CLL patients.Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy.Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.T cell modulation in immunotherapy for hematological malignancies.Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies.BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor.Role of Bruton's tyrosine kinase in B cells and malignancies.Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.Trial Watch: Adoptively transferred cells for anticancer immunotherapy.

P2860

Q26822769-4C3C64BF-17B7-43E8-ABBD-407255BD31CC Q33729598-EAE19664-5D1A-48E0-8AA1-F3B541B9F941 Q33907565-51D06FEC-FA89-4070-AD12-47F6ACD5C829 Q37040370-BDEBC2A1-5447-4258-B1D0-A4446850BB22 Q37528067-4C9BE00C-06AE-4C66-9E3E-F2AEEB75D6E4 Q38654101-A25E01B0-32C8-4FA9-93DC-3FC782D2232F Q38747333-E21423B1-0060-46BC-9912-CAC473D8A8CD Q38845812-B076D276-F6EB-4234-BCA6-D1A99D275913 Q38913549-FD8C182C-3E14-4A27-82C3-5641947E58A1 Q38945853-0AE5E599-0A0B-48CB-BA46-BB90D6020D0E Q38957129-B716073C-904C-4654-8AC1-91FD50C41C0F Q38998430-27A31394-3720-476B-88A9-75D236214F55 Q39013616-1DE24BD7-4563-4ADB-B263-28DA505B0210 Q39039017-850CBB93-F0CD-4743-946C-6274499DC9FC Q39059681-09F5A67F-8BE1-4505-9AC6-AEC037F95F08 Q39094431-4C1BA8DE-B944-43B1-A6B2-94069F93126E Q39200527-9FB1E028-70DF-4BA3-AD8F-39CDEB0BB773 Q39381251-A9B0ECD0-1F5E-4A30-9C09-6858700231EB Q39414732-66AF8CF8-2738-44DA-9ED5-9FF5EF47B034 Q40126133-3309F4BE-48BA-4425-BA3C-6F0DEB731FCF Q40205523-2D7EE87C-DCD8-4C08-89ED-47F48A238A14 Q41259289-3BB3ECE7-DD9A-4FF6-85CD-820279C33546 Q42373203-F7A7A4ED-0577-48DC-A996-74EC0D830D91 Q42375194-9C447F8C-6A21-4718-9F50-0444BC4C346D Q42909982-DD35BFBB-507E-4876-BE1A-256732DB7BDF Q45870279-91B43888-085A-426A-978B-F23D1CA55052 Q45871879-CE0AD235-375F-4573-9A47-196602859145 Q46011813-CBF2C366-FC8D-4ECD-8330-D3AB416F8391 Q46082373-C6482A12-B3A6-482A-A720-B653553167E8 Q47434135-1DD14AA1-5BC5-442C-BE69-4802B2B8466C Q47681829-A5F90FE6-A856-4399-8D1A-666EE3F3F7FC Q47875518-11C29889-E4F8-4F29-A0A7-46ED55F7AAE6 Q48188087-813D1080-D9FA-44D7-A964-79288A38715F Q48199074-DA43B351-406C-4840-A0E1-2F72C964D299 Q49546562-C554C402-2F6A-47A3-B46A-07B0DBB90CF2 Q49888075-1EABE712-2041-4DEA-8C09-1BD8CACD713C Q51455494-EF81392D-D6BE-4F96-82FF-C39DD90DB65F Q52588132-6EDE3736-B467-411C-9DF4-DAA5D96742B7 Q52715364-2EAF8A01-5D63-4F90-9CB8-E355A5D53425 Q52780137-E69FDF3E-8FFC-4101-AFD9-51DA02A0219C

P2860

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

http://www.wikidata.org/entity/Q36651344

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

@ast

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

@en

type

label

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

@ast

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

@en

prefLabel

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

@ast

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

@en

P1433

Q36651344-AD767F0B-B475-416E-9259-E45E064DC5E5

P1476

Q36651344-7FB6669C-94F5-44BB-A05C-4EAF5C090BCC

P2093

Q36651344-215C473C-1227-43AD-A94B-02B57C5BC3FE

Q36651344-3BF970C7-BE23-4F3D-BF83-DE3B59636126

Q36651344-3E40279B-22B5-44A3-B782-5A1D79F9A9B9

Q36651344-43614BD0-C4F9-439A-96F3-3C8387065754

Q36651344-69693A9C-6AC8-4D0A-91D1-0C54BE9D1188

Q36651344-6D5EB966-A14A-4593-82DA-44507BE3D932

Q36651344-86A6F2DF-285F-404D-836C-CB936E317C3B

Q36651344-91E26B15-9945-4597-B1D7-8BF956DA2F87

Q36651344-A3F66613-3791-4BCE-8CA7-4B112B413AA0

Q36651344-B9E2DA6B-E7AD-4902-B313-9EE4797D6F95

P2860

Q36651344-0305A57C-F21B-4D44-89F6-8B8D21128E2A

Q36651344-0824467D-0DAD-4121-A350-B44755EEC0E3

Q36651344-08F06BDB-94DB-4595-9EB7-A01934C0D8A7

Q36651344-0BD92259-FA95-46F0-B319-08F0DA74A151

Q36651344-0FC681E7-272A-4762-B542-2A4A202188D0

Q36651344-146D1032-ED75-452C-912D-B0E83C9EB6FE

Q36651344-17AA511A-E40E-4424-9E50-C89B57D81B82

Q36651344-1A28055E-6AAE-4451-8A41-02DD6A917EAA

Q36651344-1DA372F3-C5EA-438D-A57C-39AA76F2AE08

Q36651344-223602C3-A6B6-418B-96FA-6AC8B43C5DCC

P304

Q36651344-43F63C39-236B-4CBF-B012-3E82346CA6DD

P31

Q36651344-FDAD8B86-1F7B-429D-9B1E-BD18E0354ED7

P356

Q36651344-A8E2F9AE-FB0D-4C3D-8550-D445CE0B0E48

P407

Q36651344-09085B4B-698B-4F07-B71F-B4FB47A7EC76

P433

Q36651344-4C77B60D-6123-44C8-A700-1159745A8903

P478

Q36651344-5AE0BC8C-8CF2-4F10-82D7-DBEA1E8FE735

P50

Q36651344-02287810-05DE-4877-AACC-021EB3B3B309

Q36651344-2DAEDA24-80FC-479A-8036-047E6AAC2DE1

Q36651344-35E538AE-3C2E-4123-84A9-E208F18CFED7

Q36651344-775D3FD2-7E29-430F-9C3E-DAA7D2C986F3

Q36651344-7D5EB8E3-69BF-4532-BC22-CA87CE87967D

Q36651344-7DE2F2A7-634E-450C-B63B-365009082CF3

Q36651344-7F59A13D-5A2D-4689-A305-F635306D6C31

Q36651344-868F90E4-C11A-490A-9F4C-90F508CF70CC

Q36651344-8A0F4A70-B2BE-4AD2-8047-D70BB615526F

Q36651344-8AA0A6EB-7689-4B69-ACDC-F580413A39C3

P577

Q36651344-F9C8499A-28F4-40CA-8912-81BC5E855F5B

P698

Q36651344-D778A9FB-AA67-4909-B20A-9CFC684A3132

P921

Q36651344-7BFE973B-2F01-431B-9D48-AAC8F76A9A73

P932

Q36651344-01EA7E79-5B2C-4701-AE1C-A3586767889C

P356

BLOOD-2015-11-679134

P1433

P1476

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

@en

P2093

Amy J Johnson

http://www.w3.org/2001/XMLSchema#string

Danielle R Cook

http://www.w3.org/2001/XMLSchema#string

Jennifer A Woyach

http://www.w3.org/2001/XMLSchema#string

Jessica Hulitt

http://www.w3.org/2001/XMLSchema#string

John C Byrd

http://www.w3.org/2001/XMLSchema#string

Jun Xu

http://www.w3.org/2001/XMLSchema#string

Kami Maddocks

http://www.w3.org/2001/XMLSchema#string

Kyle A Beckwith

http://www.w3.org/2001/XMLSchema#string

Natarajan Muthusamy

http://www.w3.org/2001/XMLSchema#string

Prachi R Patel

http://www.w3.org/2001/XMLSchema#string

P2860

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses

Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

Chimeric antigen receptor T cells for sustained remissions in leukemia

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

P304

1117-1127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2015-11-679134

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

Alexandria P Cogdill

Shannon E McGettigan

Joseph A. Fraietta

Bruce L. Levine

P577

2016-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26813675

http://www.w3.org/2001/XMLSchema#string

P921

P932

4778162

http://www.w3.org/2001/XMLSchema#string